# US 2023/0416364 A1 · Methods of redirecting of il-2 to target cells of interest

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0416364 A1
- Document ID: US20230416364A1
- Status: Published application
- Kind: A1
- Application number: 18/041,433
- Filed: 2021-08-12
- Published: 2023-12-28
- Earliest claimed: 2020-08-13
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Flavio SCHWARZ; Xiaodi DENG; Pavel STROP
- Web page: https://patentgrep.com/patent/US20230416364A1

## CPC

- C07K 16/2818: {against CD28 or CD152}
- A61K 38/2013: {IL-2}
- A61P 35/00: Antineoplastic agents
- C07K 14/55: IL-2
- C07K 14/715: for cytokines; for lymphokines; for interferons
- C12N 15/86: Viral vectors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/75: containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides constructs comprising an anti-PDI antibody, or an alternative targeting moiety, fused to CD25 or an IL-2 binding fragment of CD25. Such constructs find use in treating human diseases, such as cancer.

## Claims

### Claim 1

A polypeptide construct comprising a targeting moiety and a CD25 moiety, each of which comprises one or more amino acid sequences.

### Claim 2 (depends on 1)

The polypeptide construct of claim 1 wherein the targeting moiety comprises an antibody, or an antigen binding fragment thereof.

### Claim 3 (depends on 2)

The polypeptide construct of claim 2 wherein the targeting moiety comprises an antibody that binds specifically to a target selected from the group consisting of PD-1, NKG2a, CD8a, FcRL6, CRTAM and LAG3, or an antigen binding fragment thereof.

### Claim 4 (depends on 3)

The polypeptide construct of claim 3 wherein the targeting moiety is an anti-PD-1 antibody or an antigen binding fragment thereof, wherein the anti-PD-1 antibody or antigen binding fragment comprises one or more heavy chains.

### Claim 5 (depends on 2)

The polypeptide construct of claim 2, wherein the amino acid sequence of the CD25 moiety is appended to the C-terminus of at least one heavy chain of the antibody or antigen binding fragment thereof.

### Claim 6 (depends on 5)

The polypeptide construct of claim 5 wherein the amino acid sequence of the CD25 moiety is appended to the C-terminus of both heavy chains of the anti-PD-1 antibody.

### Claim 7 (depends on 4)

The polypeptide construct of claim 4, wherein the anti-PD-1 antibody or antigen binding fragment comprises nivolumab, pembrolizumab, a PD-1 binding fragment of nivolumab, or a PD-1 binding fragment of pembrolizumab.

### Claim 8 (depends on 7)

The polypeptide construct of claim 7 wherein the PD-1 antibody comprises:
a. a heavy chain comprising a heavy chain variable domain comprising:
i. a CDRH1 of SEQ ID NO: 17;
ii. a CDRH2 of SEQ ID NO: 18;
iii. a CDRH3 of SEQ ID NO: 19; and
b. a light chain comprising a light chain variable domain comprising:
i. a CDRL1 of SEQ ID NO: 20;
ii. a CDRL2 of SEQ ID NO: 21;
iii. a CDRL3 of SEQ ID NO: 22.

### Claim 9 (depends on 8)

The polypeptide construct of claim 8 comprising;
a. a heavy chain variable domain comprising the sequence of SEQ ID NO: 23; and
b. a light chain variable domain comprising the sequence of SEQ ID NO: 24.

### Claim 10 (depends on 9)

The polypeptide construct of claim 9 comprising;
a. a heavy chain comprising the sequence of SEQ ID NO: 25; and
b. a light chain comprising the sequence of SEQ ID NO: 27.

### Claim 11 (depends on 1)

The polypeptide construct of claim 1, wherein the CD25 moiety comprises the sequence of SEQ ID NO: 14.

### Claim 12 (depends on 11)

The polypeptide construct of claim 11 wherein the human CD25 comprises the sequence of SEQ ID NO: 12.

### Claim 13 (depends on 12)

The polypeptide construct of claim 12 wherein the human CD25 comprises the sequence of SEQ ID NO: 11.

### Claim 14 (depends on 1)

The polypeptide construct of claim 1, further comprising a linker between the targeting moiety and CD25 moiety comprising the sequence of SEQ ID NO: 7.

### Claim 15 (depends on 14)

The polypeptide construct of claim 14 comprising a first construct comprising:
a. a heavy chain comprising the sequence of SEQ ID NO: 28, 29 or 30; and
b. two light chains comprising the sequence of SEQ ID NO: 27;
or a second construct comprising:
a. two heavy chains comprising the same sequence, said sequence being selected from the group consisting of SEQ ID NO: 28, 29 or 30; and
b. two light chains each comprising the sequence of SEQ ID NO: 27;
or a third construct comprising:
a. a heavy chain comprising the sequence of SEQ ID NO: 25; and
b. a heavy chain comprising the sequence of SEQ ID NO: 28, 29 or 30; and
c. two light chains comprising the sequence of SEQ ID NO: 27.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 15)

The polypeptide construct of claim 15 wherein the sequence of both antibody heavy chains are modified by the knob-into-hole approach to promote heterodimeric heavy chain pairing.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising a polypeptide construct of claim 1.

### Claim 20 (depends on 1)

A nucleic acid encoding one or more polypeptide chains of the polypeptide construct of claim 1.

### Claim 21 (depends on 20)

An expression vector comprising the nucleic acid of claim 20.

### Claim 22 (depends on 21)

A host cell comprising the expression vector of claim 21.

### Claim 23 (depends on 1, 22)

A method of making the polypeptide construct of claim 1 comprising:
a. culturing the host cell of claim 22 under conditions that allow production of the polypeptide construct; and
b. isolating the polypeptide construct.

### Claim 24 (depends on 1)

A method of treating a disease in a human subject comprising administering to the subject the polypeptide construct of claim 1.

### Claim 25 (depends on 24)

The method of claim 24 wherein the disease is cancer.

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29 (depends on 24)

The method of claim 24 wherein human IL-2 is also administered to the subject.

### Claim 30 (depends on 1)

A method of treating a disease in a human subject comprising:
a. obtaining tumor infiltrating lymphocytes (TIL) from the subject;
b. measuring IL-2 expression level in the TIL; and
c. administering the polypeptide construct of claim 1 only to subjects whose TIL exhibit IL-2 expression above a threshold level.

### Claim 31 (depends on 30)

The method of claim 30 wherein the disease is cancer.

### Claim 32

(canceled)
